Cooper Companies (NASDAQ:COO) Stock Breaks Below 50-Day Moving Average - Here's What Happened

Key Points

• Cooper Companies shares fell below their 50-day moving average, trading as low as $59.01 versus the $60.33 average, amid concerns about channel inventory reductions, earnings pressure and operational execution.
• Investor confidence is being pressured by CEO Albert White’s departure following activist investor Elliott’s involvement, as well as multiple law-firm investigations into potential securities-disclosure violations. The investigations do not establish wrongdoing.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $68.60; the company also authorized a $3 billion share buyback and recently reported quarterly EPS above estimates.

The Cooper Companies, Inc. (NASDAQ:COO - Get Free Report) shares passed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $60.33 and traded as low as $59.01. Cooper Companies shares last traded at $59.55, with a volume of 7,892,171 shares changing hands.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Neutral Sentiment: Cooper Companies is expected to report fourth-quarter results soon. Analysts reportedly anticipate a single-digit decline in earnings per share, making the upcoming release important for confirming whether recent operational issues are temporary or more persistent. Cooper Companies quarterly earnings preview
• Negative Sentiment: CEO Albert White has stepped down following pressure from activist investor Elliott Investment Management. The leadership transition adds uncertainty as Cooper works to address investor concerns about performance and strategy. Cooper Companies CEO steps down
• Negative Sentiment: Investors continue to focus on the company’s disclosure that U.S. channel inventory was being reduced. The issue was cited as a major factor behind the sharp selloff following third-quarter results and raised concerns about near-term demand, sales timing and execution. Cooper Companies scrutinized over inventory reductions
• Negative Sentiment: Several law firms, including Rosen Law Firm and Glancy Prongay Wolke & Rotter, are investigating potential securities claims related to allegations that Cooper Companies provided materially misleading business information. These announcements do not establish wrongdoing, but they increase reputational, legal and investor-sentiment risks. Cooper Companies securities investigation
• Negative Sentiment: The combination of channel destocking, a CEO departure, projected earnings pressure and multiple securities-law investigations is weighing on confidence in COO, despite the company’s prior quarterly EPS beat and full-year 2026 guidance.

Analysts Set New Price Targets

Several research analysts recently weighed in on COO shares. Stifel Nicolaus set a $70.00 price objective on Cooper Companies and gave the stock a "buy" rating in a research report on Thursday, September 10th. Zacks Research downgraded Cooper Companies from a "hold" rating to a "strong sell" rating in a research report on Friday, September 11th. Needham & Company LLC reduced their price objective on shares of Cooper Companies from $86.00 to $73.00 and set a "buy" rating on the stock in a report on Thursday, September 10th. Mizuho set a $75.00 price objective on shares of Cooper Companies and gave the company an "outperform" rating in a report on Thursday, September 10th. Finally, Weiss Ratings cut shares of Cooper Companies from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Wednesday. Four equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $68.60.

Cooper Companies Trading Down 1.3%

The company has a quick ratio of 0.73, a current ratio of 1.22 and a debt-to-equity ratio of 0.23. The business has a 50-day simple moving average of $60.33 and a 200-day simple moving average of $69.09. The company has a market cap of $11.32 billion, a PE ratio of 20.32, a price-to-earnings-growth ratio of 2.45 and a beta of 0.83.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same period last year, the business posted $0.49 earnings per share. The company's quarterly revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, analysts predict that The Cooper Companies, Inc. will post 4.53 EPS for the current fiscal year.

Cooper Companies declared that its board has initiated a stock buyback program on Wednesday, September 9th that permits the company to buy back $3 billion in outstanding shares. This buyback authorization permits the medical device company to buy up to 22.7% of its stock through open market purchases. Share buyback programs are often a sign that the company's board of directors believes its stock is undervalued.

Insider Activity at Cooper Companies

In other news, Director Paul Keel bought 4,701 shares of the company's stock in a transaction on Friday, September 11th. The stock was bought at an average cost of $53.18 per share, with a total value of $249,999.18. Following the transaction, the director directly owned 4,701 shares in the company, valued at $249,999.18. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lawrence Kurzius purchased 10,000 shares of the business's stock in a transaction on Monday, September 14th. The shares were acquired at an average price of $53.91 per share, for a total transaction of $539,100.00. Following the completion of the purchase, the director directly owned 21,099 shares of the company's stock, valued at approximately $1,137,447.09. This trade represents a 90.10% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 34,701 shares of company stock worth $1,880,039 in the last three months. 2.08% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cooper Companies

Hedge funds have recently added to or reduced their stakes in the business. Rakuten Investment Management Inc. acquired a new position in shares of Cooper Companies in the 3rd quarter valued at $1,982,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Cooper Companies in the 3rd quarter valued at $3,096,000. ProShare Advisors LLC raised its position in Cooper Companies by 2.2% in the 3rd quarter. ProShare Advisors LLC now owns 32,067 shares of the medical device company's stock valued at $1,813,000 after purchasing an additional 692 shares during the last quarter. Vise Technologies Inc. grew its position in Cooper Companies by 23.5% during the 3rd quarter. Vise Technologies Inc. now owns 6,093 shares of the medical device company's stock worth $344,000 after purchasing an additional 1,158 shares during the last quarter. Finally, International Assets Investment Management LLC grew its position in Cooper Companies by 506.0% during the 3rd quarter. International Assets Investment Management LLC now owns 23,166 shares of the medical device company's stock worth $1,310,000 after purchasing an additional 19,343 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

About Cooper Companies

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women's health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.